Pharma stock jumps 3% after receiving CDSCO approval to import and sell cancer treatment drug

The shares of a Pharmaceuticals company, specializing in the business of manufacture, distribution, and marketing of pharmaceutical products, jumped upto 3 percent upon approval from CDSCO to import and distribute a Cancer-treating Drug.

Price action

With a market capitalization of Rs. 17,099.13 crores on Monday, the shares of Astrazeneca Pharma India Ltd jumped upto 2.58 percent making a high of Rs. 6880.00 per share compared to its previous closing price of Rs. 6706.40  per share.

What Happened 

Astrazeneca Pharma India Ltd, engaged in the business of manufacture, distribution, and marketing of pharmaceutical products, has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab solution.

This approval allows the combination of Durvalumab and Tremelimumab for treating unresectable hepatocellular carcinoma (uHCC) in patients and the initial announcement was made on February 28, 2025.

Also read: Duopoly stock crashes after Goldman Sachs cuts target price amid SEBI’s proposed risk changes

About the company 

AstraZeneca Pharma India Ltd is a leading pharmaceutical company in India, focusing on the research, development, and commercialization of innovative medicines. It operates in key therapeutic areas such as oncology, cardiovascular, respiratory, and immunology. The company is part of AstraZeneca Plc, a global biopharmaceutical company, and is committed to improving patient outcomes through cutting-edge therapies.

Key Insights 

The company maintains a low debt-to-equity ratio of 0.03 and has achieved an average 3-year revenue growth of 17.16 percent. Additionally, it has experienced an impressive average 3-year net profit growth of 37.89 percent.

Financials 

The company’s revenue rose by 42.1 percent from Rs. 315.45 crore to Rs. 448.27 crore in Q3FY24-25. Meanwhile, Net profit rose from Rs. 15.8 crores to Rs. 30.85 crore during the same period. 

Written by Sridhar J 

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock jumps 3% after receiving CDSCO approval to import and sell cancer treatment drug appeared first on Trade Brains.